DOP55 The increasing burden of direct and indirect costs of IBD

Abstract Background The cost of care for inflammatory bowel disease (IBD) has nearly doubled over the last two decades. With an increasing number patients and evolving treatment paradigms utilizing costly but efficacious biologic agents earlier more often, burden is only expected to worsen. Furthermore, IBD carries significant indirect costs lost productivity their caregivers out-of-pocket healthcare expenses borne directly by patients. Methods This talk will explore current landscape drivers direct as well discuss challenges in assessing comparing such data across countries Results Direct management have shifted substantially recent years, primarily due emergence penetrance therapy into clinical practice. Despite increased use treatment, expenditure on hospitalization surgery had a relatively small impact reductions cost, mean per capita spent biologics years higher than what was saved capita. In fact, health associated with dramatically decade. New molecules are also be approved coming which likely further increase economic IBD. These may offset loss patent exclusivity infliximab adalimumab much Western world, allowed competition form biosimilar reduction prices. greatest this population relates absenteeism presenteeism among working individuals premature retirement. However, related reduced professional development personal achievement illness—as caregiver costs—are largely unknown. Conclusion expensive chronic payments rise. Treating CD remains treating UC escalate these not possible other costs. differ between systems. Indirect constitute society